Meta-analysis of studies using selective α1-blockers in patients with hypertension and type 2 diabetes

M. Glanz, A. J. Garber, G. Mancia, M. Levenstein

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This meta-analysis of published studies evaluated the effect of selective α1-blockers on lipid and carbohydrate profiles and blood pressure (BP) as well as tolerability in patients with hypertension and type 2 diabetes. Publications identified via MEDLINE were used. Text and bibliographies of retrieved articles were examined for additional references. Clinical trials with a randomised comparative structure (placebo and active treatment arms) and controlled studies with other structures were included. Of the 27 citations identified, 22 studies were selected for inclusion, and five were rejected. Efficacy and safety data, lipid and carbohydrate profiles, and study and patient characteristics were extracted by two investigators independently. The mean pooled results showed beneficial effects of selective α1-blockers on total serum cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and systolic and diastolic BP. The results also showed doxazosin had beneficial effects on fasting glucose levels, insulin sensitivity, TC, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, HDL/TC ratio, and systolic and diastolic BP. The risk difference was equivalent between the α1-blocker group and the control group for postural hypotension or syncope. This meta-analysis demonstrates a number of favourable effects of therapy with selective α1-blockers in hypertensive patients with type 2 diabetes. These agents provide an effective modality for reducing BP, with favourable effects on lipid, no deterioration in glycaemic control, and little risk of orthostatic hypotension.

Original languageEnglish
Pages (from-to)694-701
Number of pages8
JournalInternational Journal of Clinical Practice
Volume55
Issue number10
Publication statusPublished - 2001

Fingerprint

Type 2 Diabetes Mellitus
Meta-Analysis
Blood Pressure
Hypertension
Orthostatic Hypotension
Cholesterol
Lipids
HDL Cholesterol
Serum
Carbohydrates
Doxazosin
Syncope
Bibliography
HDL Lipoproteins
MEDLINE
LDL Cholesterol
Insulin Resistance
Publications
Fasting
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Meta-analysis of studies using selective α1-blockers in patients with hypertension and type 2 diabetes. / Glanz, M.; Garber, A. J.; Mancia, G.; Levenstein, M.

In: International Journal of Clinical Practice, Vol. 55, No. 10, 2001, p. 694-701.

Research output: Contribution to journalArticle

Glanz, M. ; Garber, A. J. ; Mancia, G. ; Levenstein, M. / Meta-analysis of studies using selective α1-blockers in patients with hypertension and type 2 diabetes. In: International Journal of Clinical Practice. 2001 ; Vol. 55, No. 10. pp. 694-701.
@article{3390810069d54a3f952101a8e67885ba,
title = "Meta-analysis of studies using selective α1-blockers in patients with hypertension and type 2 diabetes",
abstract = "This meta-analysis of published studies evaluated the effect of selective α1-blockers on lipid and carbohydrate profiles and blood pressure (BP) as well as tolerability in patients with hypertension and type 2 diabetes. Publications identified via MEDLINE were used. Text and bibliographies of retrieved articles were examined for additional references. Clinical trials with a randomised comparative structure (placebo and active treatment arms) and controlled studies with other structures were included. Of the 27 citations identified, 22 studies were selected for inclusion, and five were rejected. Efficacy and safety data, lipid and carbohydrate profiles, and study and patient characteristics were extracted by two investigators independently. The mean pooled results showed beneficial effects of selective α1-blockers on total serum cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and systolic and diastolic BP. The results also showed doxazosin had beneficial effects on fasting glucose levels, insulin sensitivity, TC, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, HDL/TC ratio, and systolic and diastolic BP. The risk difference was equivalent between the α1-blocker group and the control group for postural hypotension or syncope. This meta-analysis demonstrates a number of favourable effects of therapy with selective α1-blockers in hypertensive patients with type 2 diabetes. These agents provide an effective modality for reducing BP, with favourable effects on lipid, no deterioration in glycaemic control, and little risk of orthostatic hypotension.",
author = "M. Glanz and Garber, {A. J.} and G. Mancia and M. Levenstein",
year = "2001",
language = "English",
volume = "55",
pages = "694--701",
journal = "International Journal of Clinical Practice",
issn = "1368-5031",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Meta-analysis of studies using selective α1-blockers in patients with hypertension and type 2 diabetes

AU - Glanz, M.

AU - Garber, A. J.

AU - Mancia, G.

AU - Levenstein, M.

PY - 2001

Y1 - 2001

N2 - This meta-analysis of published studies evaluated the effect of selective α1-blockers on lipid and carbohydrate profiles and blood pressure (BP) as well as tolerability in patients with hypertension and type 2 diabetes. Publications identified via MEDLINE were used. Text and bibliographies of retrieved articles were examined for additional references. Clinical trials with a randomised comparative structure (placebo and active treatment arms) and controlled studies with other structures were included. Of the 27 citations identified, 22 studies were selected for inclusion, and five were rejected. Efficacy and safety data, lipid and carbohydrate profiles, and study and patient characteristics were extracted by two investigators independently. The mean pooled results showed beneficial effects of selective α1-blockers on total serum cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and systolic and diastolic BP. The results also showed doxazosin had beneficial effects on fasting glucose levels, insulin sensitivity, TC, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, HDL/TC ratio, and systolic and diastolic BP. The risk difference was equivalent between the α1-blocker group and the control group for postural hypotension or syncope. This meta-analysis demonstrates a number of favourable effects of therapy with selective α1-blockers in hypertensive patients with type 2 diabetes. These agents provide an effective modality for reducing BP, with favourable effects on lipid, no deterioration in glycaemic control, and little risk of orthostatic hypotension.

AB - This meta-analysis of published studies evaluated the effect of selective α1-blockers on lipid and carbohydrate profiles and blood pressure (BP) as well as tolerability in patients with hypertension and type 2 diabetes. Publications identified via MEDLINE were used. Text and bibliographies of retrieved articles were examined for additional references. Clinical trials with a randomised comparative structure (placebo and active treatment arms) and controlled studies with other structures were included. Of the 27 citations identified, 22 studies were selected for inclusion, and five were rejected. Efficacy and safety data, lipid and carbohydrate profiles, and study and patient characteristics were extracted by two investigators independently. The mean pooled results showed beneficial effects of selective α1-blockers on total serum cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and systolic and diastolic BP. The results also showed doxazosin had beneficial effects on fasting glucose levels, insulin sensitivity, TC, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, HDL/TC ratio, and systolic and diastolic BP. The risk difference was equivalent between the α1-blocker group and the control group for postural hypotension or syncope. This meta-analysis demonstrates a number of favourable effects of therapy with selective α1-blockers in hypertensive patients with type 2 diabetes. These agents provide an effective modality for reducing BP, with favourable effects on lipid, no deterioration in glycaemic control, and little risk of orthostatic hypotension.

UR - http://www.scopus.com/inward/record.url?scp=0035664117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035664117&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 694

EP - 701

JO - International Journal of Clinical Practice

JF - International Journal of Clinical Practice

SN - 1368-5031

IS - 10

ER -